The PSD-95 inhibitor also had a favorable safety profile in phase III trial ...

Stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, daily for 10 days and starting ...

Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and ...

The factor XIa inhibitor asundexian reduced recurrent ischemic stroke without increasing major or minor bleeding in patients ...

An investigational anti-clotting medication, asundexian, demonstrated a reduction in the risk of a second ischemic ...

AIM: The “2026 Guideline for the Early Management of Patients With AIS” replaces the “2018 Guidelines for the Early Management of Patients With AIS” and the 2019 update to reflect recent advances in ...

The rationale behind the treatment is that, because genetic FXI deficiency has been linked with reduced risk of ischemic ...

TIGERTRIEVER (TM) 13 is the first device shown to meet safety and effectiveness endpoints for restoring blood flow in smaller but critical areas of the brain, accounting for almost 50% of all ischemic ...

This “long overdue” update expands the pools of patients eligible for thrombolysis and thrombectomy, and tackles pediatric ...

Expanded eligibility for advanced ischemic stroke therapies and the first detailed recommendations pediatric stroke care are ...

Women with a previous history of ischemic stroke have doubled odds of having another ischemic stroke during pregnancy or early postpartum.

When lesion size and location were matched, hemorrhagic stroke produced worse 3 month disability and higher DALYs than ...